Renal-cell carcinoma is characterized by a lack of early-warning signs (which results in a
high proportion of patients with metastases), diverse clinical manifestations, and resistance to …

We describe the development and clinical translation of a targeted polymeric nanoparticle (TNP)
containing the chemotherapeutic docetaxel (DTXL) for the treatment of patients with …

Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that
was initially characterized by the monoclonal antibody (mAb) 7E11. PSMA is highly …

Prostate-specific membrane antigen (PSMA), initially defined by monoclonal antibody (mAb)
7E11, is a now well-characterized type 2 integral membrane glycoprotein expressed in a …

Of 133 patients with advanced urothelial tract cancer given methotrexate (MTX), vinblastine (VBL),
Adriamycin (ADR) (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (…

A single, high linear energy transfer alpha particle can kill a target cell. We have developed
methods to target molecular-sized generators of alpha-emitting isotope cascades to the …

Purpose To determine the maximum tolerated dose (MTD), toxicity, human anti-J591 response,
pharmacokinetics (PK), organ dosimetry, targeting, and biologic activity of 177Lutetium-…

The androgen receptor (AR) plays a central role in establishing an oncogenic cascade that
drives prostate cancer progression. Some prostate cancers escape androgen dependence …

Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein expressed
predominantly by prostate cancer cells. We have characterized four monoclonal antibodies that …

… Neil Bander is the inventor on patents that are owned by Cornell Research Foundation (CRF)
for the J591 antibody described in this manuscript. Dr. Neil Bander is a paid consultant to …